DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "US Fabry Disease Market and Competitive Landscape Highlights - 2016" drug pipelines to their offering.
US Fabry Disease Market and Competitive Landscape Highlights - 2016 provides comprehensive insights into Fabry Disease pipeline products, Fabry Disease epidemiology, Fabry Disease market valuations and forecast, Fabry Disease products sales and competitive landscape in the US.
The research is classified into nine sections - Fabry Disease overview including etiology, pathophysiology, and diagnosis, Fabry Disease treatment options, Fabry Disease pipeline products, Fabry Disease market analysis comprising of Fabry Disease epidemiology, key products marketed for Fabry Disease, market valuations and forecast, products sales and market shares.
Research Scope:
- Fabry Disease Pipeline: Find out the products in clinical trials for the treatment of Fabry Disease by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
- Fabry Disease Epidemiology: Find out the number of patients diagnosed (prevalence) with Fabry Disease in the US
- Fabry Disease Products: Identify key products marketed and prescribed for Fabry Disease in the US, including trade name, molecule name, and company
- Fabry Disease Product Sales: Find out the sales revenues of Fabry Disease products, both branded and generics, in the US
- Fabry Disease Market Valuations: Find out the market size for Fabry Disease products in 2015 in the US. Find out how the market advanced from 2010 and forecast to 2020
- Fabry Disease Products Market Share: Find out the market shares for key Fabry Disease products in the US
Key Topics Covered:
- Disease Overview
- Fabry Disease Treatments
- Fabry Disease Pipeline
- US Fabry Disease Epidemiology
- Marketed Drugs for Fabry Disease in US
- US Fabry Disease Market Size
- US Fabry Disease Products Sales
- US Fabry Disease Market Competitive Landscape
- US Fabry Disease Market Forecast
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/zwvdj9/us_fabry_disease
